Income statement
USD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 17M | 0 | 0 | 0 | 0 |
| Gross Profit | 11M | 0 | 0 | 0 | 0 |
| Operating Income | -32M | -8M | -7M | -2M | -839K |
| EBITDA | -30M | -7M | -7M | -2M | -595K |
| Net Income | -43M | -8M | -7M | -2M | -595K |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$29.00
+7.37% today
1Y Change
+147.86%
Window
Jun 23, 2025 → Jun 18, 2026
Coverage: 249 bars · Jun 23, 2025 → Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Pelthos Therapeutics Inc. (PTHS) is a Healthcare stock with a market cap of $20.00M and listed on AMEX. The stock last traded around $29.00 and up 147.9% across the available one-year price window (Jun 23, 2025 → Jun 18, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of -70.2%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS -70.2%, free cash flow -291.7% with operating margin -193.1% and ROIC -26.4%. Valuation is more restrained than many high-expectation growth names at price/sales 1.0. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines PTHS price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
PTHS
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
PTHS Max Drawdown
-51.39%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for PTHS and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
-$595.4K
+75.8% YoY
Free Cash Flow
-$1.6M
-59.7% YoY
Revenue Growth
+0.0%
EPS Growth
-70.2%
Gross Margin
62.6%
Net Margin
-257.9%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 17M | 0 | 0 | 0 | 0 |
| Gross Profit | 11M | 0 | 0 | 0 | 0 |
| Operating Income | -32M | -8M | -7M | -2M | -839K |
| EBITDA | -30M | -7M | -7M | -2M | -595K |
| Net Income | -43M | -8M | -7M | -2M | -595K |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Cash & Equivalents | 18M | 513K | 96K | 55K |
| Total Assets | 130M | 1M | 96K | 55K |
| Total Liabilities | 92M | 4M | 7M | 4M |
| Shareholder Equity | 39M | -3M | -6M | -4M |
| Total Debt | 35M | 2M | 1M | 540K |
| Net Debt | 17M | 2M | 1M | 485K |
Cash flow positioning
Latest Full Year
Operating Cash Flow
2M
-59.7% YoY
Capital Expenditures
0
Free Cash Flow
2M
-59.7% YoY
Key ratios
Gross Margin
62.6%
Operating Margin
-193.1%
Net Margin
-257.9%
ROE
-200.4%
Debt / Equity
0.90x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.